RecruitingPhase 1NCT07528508

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

A Clinical Trial to Study the Effect of a Single Dose of MK-8527 on the Pharmacokinetics of Methadone

Sponsor

Merck Sharp & Dohme LLC

Enrollment

14 participants

Start Date

May 22, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

The goal of this study is to learn about the effect of a study medicine called MK-8527 when taken with methadone. The study will also measure what happens to the methadone in a healthy person's body over time after MK-8527 is taken.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria1

Has a body-mass index (BMI) between 18 and 35 kg/m\^2

Exclusion Criteria4

Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Has a history of cancer (malignancy)
Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food
Has a positive test(s) for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)

Interested in this trial?

Get notified about updates and connect with the research team.